Tag Archive for: appointments

Biocomposites appoints two new Directors to strengthen its team for its next phase of growth

Michelle Lewis becomes Human Resources Director Ciara Airey becomes Regulatory Affairs Director Keele, UK, 2 August 2023 – Biocomposites, an international medical devices company that engineers, manufactures and markets world leading products for use in infection management in bone and soft tissue, has strengthened its leadership team with the addition of two new Directors. Michelle Lewis […]

IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer

Eric Faulkner, currently Sr. Vice President, CMC, appointed as Chief Technical Officer NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced the appointment of Qasim Ahmad, MD, as Chief Medical Officer. Dr. Ahmad joins IO […]

Versameb Strengthens its Board of Directors

Significant appointments of experienced drug development and financial experts – Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD, MBA and Dr Alexandre LeBeaut Versameb AG (“Versameb”), transforming (m)RNA therapeutics to cure hard-to-treat and/or prevalent diseases, is pleased to announce the appointments of Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD, MBA and Dr Alexandre LeBeaut to its […]

Breye Therapeutics Strengthens Management Team and Board

Industry veteran Dr. Peter Adamson, PhD appointed as Chief Scientific Officer Dr. Gabriela Burian, MD appointed to the Board of Directors Copenhagen, Denmark, 20 April 2023 – Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces the appointment of Peter Adamson as Chief Scientific […]

Gadeta Appoints Scientific Advisory Board and Provides Business Update

Utrecht, Netherlands and Boston, Mass., 20 October 2022: Gadeta B.V. (‘Gadeta’), an innovative clinical-stage biopharmaceutical company pioneering the development of gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for solid tumors, today announced the formation of a Scientific Advisory Board comprised of internationally renowned leaders in oncology, T cell biology and strategic drug development. The Scientific […]